{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.4","upperLimit":"57.9","value":"14.3"},{"groupId":"OG001","lowerLimit":"39.7","upperLimit":"71.5","value":"56.1"},{"groupId":"OG002","lowerLimit":"47.1","upperLimit":"86.8","value":"69.6"},{"groupId":"OG003","lowerLimit":"19.4","upperLimit":"99.4","value":"75.0"},{"groupId":"OG004","lowerLimit":"0.0","upperLimit":"41.0","value":"0"},{"groupId":"OG005","lowerLimit":"16.5","upperLimit":"54.0","value":"33.3"},{"groupId":"OG006","lowerLimit":"6.8","upperLimit":"49.9","value":"23.5"},{"groupId":"OG007","lowerLimit":"0.0","upperLimit":"26.5","value":"0.0"},{"groupId":"OG008","lowerLimit":"0.0","upperLimit":"52.2","value":"0.0"},{"groupId":"OG009","lowerLimit":"1.1","upperLimit":"29.2","value":"9.1"},{"groupId":"OG010","lowerLimit":"0.3","upperLimit":"52.7","value":"12.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"27"},{"groupId":"OG006","value":"17"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"22"},{"groupId":"OG010","value":"8"}],"units":"Participants"}],"description":"ORR is defined as the proportion of subjects with CR or PR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in Cohort 1 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15, plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.","id":"OG000","title":"Cohort 1 - Safety Lead-in (TTX-030 + Budigalimab + mFOLFOX6)"},{"description":"Participants in Cohort 3B were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15, plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.","id":"OG001","title":"Cohort 3B - Gastric (TTX-030 + Budigalimab + mFOLFOX6)"},{"description":"Participants in Cohort 12 were administered IV budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.","id":"OG002","title":"Cohort 12 - Gastric (Budigalimab + mFOLFOX6)"},{"description":"Participants in Cohort 3A were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.","id":"OG003","title":"Cohort 3A - Gastric (TTX-030 + mFOLFOX6)"},{"description":"Participants in Safety Lead-in Cohort 2 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab 375mg Q3W plus docetaxel at a dose of 75 mg/m2 Q3W on Day 1 of each 21-day treatment cycle.","id":"OG004","title":"Cohort 2 - mCRPC (TTX-030 + Budigalimab + Docetaxel)"},{"description":"Participants in Cohort 9 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus gemcitabine 1000 mg/m2 + nab-paclitaxel 125 mg/m2 on Days 1, 8, and 15 each 28-day cycle.","id":"OG005","title":"Cohort 9 - Pancreatic (TTX-030 + Budigalimab + Gemcitabine + Nab-Paclitaxel)"},{"description":"Participants in Cohort 11 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus gemcitabine 1000 mg/m2 + nab-paclitaxel 125 mg/m2 on Days 1, 8, and 15 each 28-day cycle.","id":"OG006","title":"Cohort 11 - Pancreatic (TTX-030 + Gemcitabine + Nab-Paclitaxel)"},{"description":"Participants in Cohort 4 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.","id":"OG007","title":"Cohort 4 - CRC (TTX-030 + Budigalimab)"},{"description":"Participants in Cohort 6 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.","id":"OG008","title":"Cohort 6 - HNSCC (TTX-030 + Budigalimab)"},{"description":"Participants in Cohort 8 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.","id":"OG009","title":"Cohort 8 - GEC (TTX-030 + Budigalimab)"},{"description":"Participants in Cohort 10 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus pembrolizumab at a dose of 200 mg Q3W on Day 1 of each 21-day treatment cycle.","id":"OG010","title":"Cohort 10 - UCC (TTX-030 + Pembrolizumab)"}],"paramType":"NUMBER","populationDescription":"The ORR was defined as the proportion of participants who achieved a BOR of either CR or PR as derived based on the lesion measurement provided by the Investigator per RECIST v1.1. Confirmed ORR was defined as 2 disease response assessments showing objective response (CR or PR) at least 4 weeks apart and was presented with corresponding 2-sided 95% confidence intervals (CIs) based on the Clopper-Pearson method.","reportingStatus":"POSTED","timeFrame":"Through study completion, an average of 1 year","title":"Confirmed Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}